Description

Lumiliximab is a chimeric monoclonal antibody designed for targeted therapeutic applications. This compound is of significant interest in the research and development of novel immunotherapies, particularly for hematological malignancies. It is primarily utilized by pharmaceutical researchers, biotechnology companies, and academic institutions engaged in preclinical and clinical studies for targeted cancer treatment.

Application

• Biopharmaceutical Research: A key reagent in the investigation of B-cell signaling pathways and apoptosis induction.
• Oncology Drug Development: Serves as a critical component in the preclinical evaluation of therapies for chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
• Immunology Studies: Used to study CD23 (FcεRII) receptor interactions and their role in immune regulation.
• Clinical Trial Material: Acts as a reference standard or active pharmaceutical ingredient (API) in the formulation of investigational new drugs (INDs).
• Bioconjugation & ADC Development: Potential use as a base antibody for the creation of antibody-drug conjugates (ADCs) targeting specific cell types.

Basic Information

Product Name	Lumiliximab
CAS No.	357613-86-6
Molecular Formula	C6450H9936N1720O2016S44
Molecular Weight	Approx. 145 kDa
Synonyms	Anti-CD23 Monoclonal Antibody; Anti-FCER2 Monoclonal Antibody; IDEC-152; Chimeric Anti-CD23 Antibody; Anti-Human CD23 Antibody; Anti-FcεRII Antibody; Therapeutic Monoclonal Antibody IDEC-152
EINECS	Contact for details

Quality Control

Our Lumiliximab is produced and tested under stringent quality management systems to ensure batch-to-batch consistency and biological activity. Each lot is characterized for identity, purity, potency, and stability. Comprehensive analysis includes SDS-PAGE, size-exclusion HPLC (SE-HPLC), and binding affinity assays. A detailed Certificate of Analysis (COA) is provided with every shipment, confirming compliance with relevant specifications for research and development use.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized material at -20°C or below. Reconstituted solutions should be aliquoted and stored at -80°C to avoid repeated freeze-thaw cycles. This product is hygroscopic (moisture-sensitive); ensure containers are sealed under inert atmosphere or with desiccant when applicable.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (SDS-PAGE)	Corresponds to reference standard
Purity (SE-HPLC)	≥ 95% Monomer
Protein Content (UV Absorbance)	≥ 1.0 mg/vial
Endotoxin (LAL Test)	< 1.0 EU/mg
Biological Activity (Binding Assay)	Meets acceptance criteria
Moisture Content (Karl Fischer)	< 3.0 %

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.